SHL Medical Market Research Report

Company Overview

Company Name:

SHL Medical

Mission:

We enable patients' independence by designing, developing, and manufacturing advanced self-injection solutions including autoinjectors, pen injectors, and innovative specialty delivery systems for large-volume and high-viscosity formulations.

Founding:

Year Founded: 1989

Founder: Roger Samuelsson

Key People:

Ulrich Faessler - Chief Executive Officer

Ralph Howald - Chief Technology Officer

Said Djaouat - Chief Quality & Regulatory Officer

Satbir Bains - Chief Human Resources Officer

Markus Puusepp - Chief Growth Officer

Martin Turvill - Chief Operating Officer

Dietmar Bettio - Chief Digital Transformation Officer

Sébastien Martin - Chief Digital Implementation Officer

Anne Pagenkemper - Chief Financial Officer

Barbara Lange - Chief Legal Officer

Headquarters:

Gubelstrasse 22, 6300 Zug, Switzerland

Number of Employees:

Over 6,000 employees worldwide

Revenue:

No information is available

Notable Expertise:

SHL Medical is a pioneering leader known for its expert design and manufacturing of self-injection devices including autoinjectors like Molly®, Maggie®, and Elexy™.

Products

Autoinjectors:

1. Molly®

Modular platform technology

Ergonomic body

Medium viscosity & volume: 1.0 ml

Primary Container: Pre-Filled Syringe (PFS)

Key features: Disposable, user-friendly, customization options

2. Molly® 2.25

Large-volume variant

Medium viscosity & volume: 2.25 ml

Primary Container: PFS

Two-step operation for easy use

3. Molly® Connected Cap

Connected add-on for Molly devices

Bluetooth® beacon connectivity

Promotes data transfer and remote monitoring

4. Maggie®

Innovative Needle Isolation Technology (NIT®)

High viscosity & volume: 3.0 ml

Proprietary cartridge system

5. Maggie® 5.0

Larger variant accommodating up to 5.0 ml

High viscosity formulation

6. Elexy™

Versatile electromechanical device

Reusable power unit

Up to 5.0 ml capacity

Compatibility with PFS and cartridges

Recent Developments

Innovations:

Elexy™: A best-in-class electromechanical autoinjector developed for versatile use, featuring an integrated connectivity system for therapy monitoring.

Molly® Connected Cap: Provides timestamp data transmission to the cloud, enhancing connectivity and adherence monitoring in healthcare treatments.

New Partnerships:

Collaboration with SCHOTT Pharma for optimizing large-volume injection performance.

Strategic partnership with BD for delivering higher viscosities using 8 mm PFS.

Partnership with AARDEX Group to integrate medication adherence software.

Recent Launches:

Elexy™ launched as a flexible, high-connectivity autoinjector system.

Molly® Connected Cap launched to improve patient adherence through connected data insights.

Geographic Presence and Expansion

Global footprint with locations in Europe (Switzerland, Sweden), the Americas (USA, Mexico), and Asia (Taiwan, China).

Expanding global network to enhance manufacturing capabilities across multiple continents.

Commitment to Sustainability

Targets for 2030 include 100% renewable energy usage, reducing GHG emissions by 42%, and aligning with global sustainability initiatives like the UN Global Compact and Science Based Targets initiative.

Innovation Leadership

Holds 227 active patent families for single-use autoinjectors

Development of future-oriented solutions addressing unmet patient needs worldwide.

This report provides a snapshot of SHL Medical's leadership in the self-injection device market, showcasing the company's commitment to patient independence, innovation, and global collaboration in advancing healthcare solutions.